Biodelivery Sciences International Inc BDSI
We take great care to ensure that the data presented and summarized in this overview for BIODELIVERY SCIENCES INTERNATIONAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BDSI
Top Purchases
Top Sells
About BDSI
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
Insider Transactions at BDSI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2022
|
Jeffrey Allen Bailey Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
105,133
-100.0%
|
-
|
|
Mar 22
2022
|
Todd C Davis Director |
SELL
Other acquisition or disposition
|
Direct |
252,207
-100.0%
|
-
|
|
Mar 22
2022
|
Peter Greenleaf Director |
SELL
Other acquisition or disposition
|
Direct |
105,034
-100.0%
|
-
|
|
Mar 22
2022
|
Kevin Kotler Director |
SELL
Other acquisition or disposition
|
Indirect |
7,588,395
-100.0%
|
-
|
|
Mar 22
2022
|
Scott M. Plesha Officer |
SELL
Other acquisition or disposition
|
Direct |
345,127
-100.0%
|
-
|
|
Mar 22
2022
|
Mark A Sirgo Director |
SELL
Other acquisition or disposition
|
Direct |
1,166,866
-100.0%
|
-
|
|
Mar 22
2022
|
Thomas B Smith Chief Medical Officer |
SELL
Other acquisition or disposition
|
Direct |
52,530
-100.0%
|
-
|
|
Mar 22
2022
|
Vanila Singh Director |
SELL
Other acquisition or disposition
|
Direct |
35,851
-100.0%
|
-
|
|
Mar 22
2022
|
W. Mark Watson Director |
SELL
Other acquisition or disposition
|
Direct |
90,663
-100.0%
|
-
|
|
Mar 09
2022
|
Jeffrey Allen Bailey Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,333
+4.83%
|
-
|
|
Feb 11
2022
|
Kevin Kotler Director |
BUY
Conversion of derivative security
|
Indirect |
2,422,222
+24.2%
|
$2,422,222
$1.8 P/Share
|
|
Feb 04
2022
|
James Vollins Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,872
-100.0%
|
$29,616
$3.66 P/Share
|
|
Feb 04
2022
|
James Vollins Officer |
SELL
Open market or private sale
|
Direct |
18,541
-65.26%
|
$55,623
$3.6 P/Share
|
|
Jan 31
2022
|
Scott M. Plesha Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,203
+3.45%
|
-
|
|
Jan 31
2022
|
James Vollins Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,137
+18.57%
|
-
|
|
Jan 31
2022
|
Thomas B Smith Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,215
+13.57%
|
-
|
|
Jan 27
2022
|
Todd C Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,684
+2.96%
|
-
|
|
Jan 27
2022
|
Scott M. Plesha Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,050
+6.16%
|
-
|
|
Jan 27
2022
|
James Vollins Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,276
+50.0%
|
-
|
|
Jan 27
2022
|
Thomas B Smith Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,361
+31.75%
|
-
|